Want to see HK:2228 full AI Analyst Report?
QuantumPharm, Inc. (2228) AI Stock Analysis
Top Page
QuantumPharm, Inc.
(HKEX:2228)
The score is driven primarily by mixed financial performance: strong top-line and gross profit expansion and a much stronger balance sheet are offset by persistent operating losses and ongoing negative operating/free cash flow. Technicals are mildly supportive in the short term but remain weaker over longer horizons, and valuation is constrained by a negative P/E and no dividend yield data.
QuantumPharm, Inc. (2228) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 26.30B
- Dividend Yield
- ―
- Average Volume (3M)
- 58.26M
- Price to Earnings (P/E)
- -100.8
- Beta (1Y)
- 1.74
- Revenue Growth
- 3.85%
- EPS Growth
- 6.86%
- Country
- Hong Kong
- Employees
- 1,254
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
QuantumPharm, Inc. Business Overview & Revenue Model
Company Description
XtalPi Holdings Limited functions as an investment holding company, delivering sophisticated drug discovery and intelligent automation solutions across key markets including China, the United States, Europe, South Korea, and Japan. Its comprehensive...
QuantumPharm, Inc. Financial Statement Overview
Summary
Revenue and gross profit surged in 2025, and the balance sheet improved materially with high equity relative to debt. However, operating profitability remains deeply negative and operating/free cash flow are still negative (continued cash burn), which keeps overall financial quality below average despite the rebound.
Income Statement
34NegativeBalance Sheet
58NeutralCash Flow
26Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 668.98M | 781.85M | 266.43M | 174.42M | 133.35M | 62.80M |
| Gross Profit | 344.67M | 544.71M | 123.43M | 48.24M | 66.09M | 32.78M |
| EBITDA | -274.74M | 253.59M | -575.30M | -1.78B | -1.38B | -2.11B |
| Net Income | -208.16M | 120.54M | -1.52B | -1.91B | -1.44B | -2.14B |
Balance Sheet | ||||||
| Total Assets | 12.62B | 10.22B | 4.35B | 4.01B | 4.32B | 4.38B |
| Cash, Cash Equivalents and Short-Term Investments | 8.67B | 7.07B | 3.10B | 2.83B | 3.47B | 3.83B |
| Total Debt | 3.12B | 443.46M | 148.76M | 11.04B | 9.45B | 7.83B |
| Total Liabilities | 3.53B | 786.95M | 362.43M | 11.25B | 9.63B | 7.99B |
| Stockholders Equity | 9.00B | 9.39B | 3.96B | -7.27B | -5.33B | -3.61B |
Cash Flow | ||||||
| Free Cash Flow | -359.21M | -199.96M | -536.79M | -698.20M | -627.83M | -417.42M |
| Operating Cash Flow | -279.77M | -139.62M | -478.68M | -567.56M | -429.10M | -253.75M |
| Investing Cash Flow | -4.44B | -3.87B | 74.09M | 735.58M | -2.76B | -70.47M |
| Financing Cash Flow | 5.11B | 5.43B | 840.00M | -25.89M | 57.99M | 2.48B |
QuantumPharm, Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2228, the sentiment is Negative. The current price of 6.12 is below the 20-day moving average (MA) of 6.59, below the 50-day MA of 7.15, and below the 200-day MA of 8.66, indicating a bearish trend. The MACD of -0.37 indicates Positive momentum. The RSI at 38.44 is Neutral, neither overbought nor oversold. The STOCH value of 78.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2228.
QuantumPharm, Inc. Peers Comparison
Overall Rating
HK:024175Outperform
HK:183370Outperform
HK:215860Neutral- HK:222845Neutral
HK:238945Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:0241 | 75Outperform | HKD 45.68B | 20.09 | 10.95% | 2.43% | 14.03% | 36.55% |
| HK:1833 | 70Outperform | HKD 11.76B | 20.98 | 4.62% | ― | 7.92% | 152.75% |
| HK:2158 | 60Neutral | HKD 3.05B | 36.94 | 1.88% | 1.40% | 16.87% | ― |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| HK:2228 | 45Neutral | HKD 26.26B | -100.75 | -2.26% | ― | 3.85% | 6.86% |
| HK:2389 | 45Neutral | HKD 448.35M | -4.35 | -6.22% | ― | -27.63% | -16.33% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:2228 | QuantumPharm, Inc. | 6.12 | -5.29 | -46.41% | |
| HK:0241 | Alibaba Health Information Technology | 2.83 | -2.66 | -48.51% | |
| HK:1833 | Ping An Healthcare and Technology Company | 5.44 | -8.98 | -62.27% | |
| HK:2389 | Beijing Health (Holdings) Limited | 0.07 | -0.00 | -2.63% | |
| HK:2158 | Yidu Tech, Inc. | 2.86 | -2.95 | -50.77% | |
| HK:2506 | Xunfei Healthcare Technology Co., Ltd. | 64.15 | -22.05 | -25.58% |
QuantumPharm, Inc. Corporate Events
XtalPi Chairman Boosts Stake in HK$25 Million Share Purchase
XtalPi Holdings Limited has announced that its chairman, executive director and co-founder, Dr. Wen Shuhao, has further increased his stake in the company under a previously disclosed shareholding increase plan. Using personal funds, Dr. Wen purchase...
XtalPi Chairman Boosts Stake in Hong Kong-Listed Tech Group
XtalPi Holdings Limited has disclosed that its chairman, executive director and co-founder, Dr. Wen Shuhao, has acquired 1,300,000 ordinary shares on the open market for approximately HK$9.5 million using his own funds. The purchase marks the first t...
XtalPi Grants New Share Options and RSUs Under 2026 Incentive Scheme
XtalPi Holdings has granted 668,920 share options to five employees and 453,890 restricted share units to eight employees under its 2026 Share Scheme, with none of the grantees being directors, chief executives or substantial shareholders. The awards...
XtalPi Chairman Plans Up to HK$32 Million Share Purchase to Signal Long-Term Confidence
XtalPi Holdings Limited has announced that its chairman, executive director and co-founder, Dr. Wen Shuhao, plans to increase his stake in the company by purchasing ordinary shares on the open market using his own funds. The planned purchases, to be...
XtalPi’s LCC Technologies Seals AI-Driven Drug Discovery Pact with Stanford
XtalPi Holdings Limited announced that its wholly owned subsidiary LCC Technologies has entered into a strategic drug discovery collaboration with Stanford University, combining Stanford’s disease biology research with LCC’s automated and...
XtalPi Swings to Loss as R&D Spending Surges in Push into AI for Science
XtalPi Holdings Limited reported interim unaudited results for the six months ended June 30, 2026, showing revenue of RMB393.6 million, down from RMB517.1 million a year earlier. The group swung to a loss of RMB224.9 million from a prior-period profi...
XtalPi Sets August Board Meeting to Approve Interim Results and Potential Dividend
XtalPi Holdings Limited has scheduled a board meeting for 19 August 2026 to review and approve the group’s interim financial results for the six months ended 30 June 2026 and to authorize their publication. The board will also consider whether...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 19, 2026